Genomed (WAR:GEN) Total Equity: zł14.07 Mil (As of Mar. 2026)


WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł26.20
GF Value zł37.83
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Total Equity?

Genomed WAR:GEN 75 Total Equity is zł14.07 Mil as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł37.83 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Genomed's total equity for the quarter that ended in Mar. 2026 was zł14.07 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Genomed Total Equity Historical Data

* Premium members only.

The historical data trend for Genomed's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Total Equity Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.80 9.14 10.06 10.72 14.12

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.96 11.02 12.45 14.12 14.07
WAR:GEN
75GF Score
Genomed SA WAR:GEN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Genomed's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=16.526-2.409
=14.12

Genomed's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=15.79-1.721
=14.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł14.07 Mil mean?
Genomed (WAR:GEN) has a Total Equity of zł14.07 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Genomed and its competitors.
Is Genomed's Total Equity too high?
Genomed's current Total Equity is zł14.07 Mil. Overall, Genomed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Total Equity compare to TMO and DHR?
Genomed's Total Equity of zł14.07 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Genomed and its competitors. Genomed's current Total Equity is zł14.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.83, compared to a current price of zł26.20 — trading 30.7% below its estimated fair value. The current Total Equity is zł14.07 Mil. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Total Equity is zł14.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł26.20 is trading 30.7% below its estimated GF Value™ of zł37.83. GuruFocus considers Genomed to be Significantly Undervalued.

Key valuation signals for WAR:GEN:

  • Total Equity: zł14.07 Mil
  • GF Value™: zł37.83 vs. price of zł26.20 (30.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł26.20
Price
zł37.83
GF Value